Vanda Pharmaceuticals (VNDA) Reaches New 12-Month High After Earnings Beat

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) hit a new 52-week high on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $25.07 and last traded at $23.98, with a volume of 64946 shares changing hands. The stock had previously closed at $20.45.

The biopharmaceutical company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.18. The company had revenue of $49.13 million for the quarter, compared to analyst estimates of $49.44 million. Vanda Pharmaceuticals had a net margin of 0.73% and a return on equity of 0.68%. Vanda Pharmaceuticals’s revenue was up 18.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.03) earnings per share.

A number of equities analysts have recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Vanda Pharmaceuticals in a report on Thursday. They set a “buy” rating and a $26.00 price target on the stock. Zacks Investment Research lowered shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday. Oppenheimer set a $27.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 2nd. Seaport Global Securities reissued a “buy” rating and set a $26.00 target price on shares of Vanda Pharmaceuticals in a research note on Thursday, August 2nd. Finally, Stifel Nicolaus reissued a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, October 31st. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $27.43.

A number of hedge funds and other institutional investors have recently made changes to their positions in VNDA. First Manhattan Co. raised its stake in Vanda Pharmaceuticals by 478,333.0% during the second quarter. First Manhattan Co. now owns 956,866 shares of the biopharmaceutical company’s stock worth $18,228,000 after buying an additional 956,666 shares during the last quarter. BlackRock Inc. increased its stake in Vanda Pharmaceuticals by 16.3% in the second quarter. BlackRock Inc. now owns 4,960,924 shares of the biopharmaceutical company’s stock valued at $94,506,000 after purchasing an additional 693,922 shares in the last quarter. Wells Fargo & Company MN increased its stake in Vanda Pharmaceuticals by 396.9% in the third quarter. Wells Fargo & Company MN now owns 652,305 shares of the biopharmaceutical company’s stock valued at $14,971,000 after purchasing an additional 521,040 shares in the last quarter. Macquarie Group Ltd. increased its stake in Vanda Pharmaceuticals by 12.1% in the second quarter. Macquarie Group Ltd. now owns 2,555,004 shares of the biopharmaceutical company’s stock valued at $48,673,000 after purchasing an additional 276,057 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in Vanda Pharmaceuticals by 336.0% in the third quarter. Acadian Asset Management LLC now owns 197,411 shares of the biopharmaceutical company’s stock valued at $4,531,000 after purchasing an additional 152,137 shares in the last quarter. 93.92% of the stock is owned by institutional investors and hedge funds.

The company has a market cap of $1.05 billion, a price-to-earnings ratio of -67.03 and a beta of 1.06.

COPYRIGHT VIOLATION NOTICE: “Vanda Pharmaceuticals (VNDA) Reaches New 12-Month High After Earnings Beat” was published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://sportsperspectives.com/2018/11/09/vanda-pharmaceuticals-vnda-reaches-new-12-month-high-after-earnings-beat.html.

Vanda Pharmaceuticals Company Profile (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Recommended Story: Stock Symbol

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply